9.30Open9.40Pre Close9 Volume0 Open Interest21.00Strike Price8.45KTurnover2800.92%IV-1.20%PremiumJul 26, 2024Expiry Date9.77Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9777Delta0.0086Gamma3.13Leverage Ratio-8.1826Theta0.0000Rho3.06Eff Leverage0.0001Vega
Pfizer Stock Discussion
PFE us at resistance, 30.70
Earnings soon, stars aligned
above 50 EMA
When PFE turns, it will move hard and fast. a lot of pressure has been built up over the 1.5-year drop.
This treatment for patients with hemophilia A appears to have the efficacy and safety metrics in place to warrant a potential approval.
Notably, Sangamo’s candidate is being developed alongside $Pfizer(PFE.US)$ , adding a layer of clout to the R&D behind the prospective treatment.
Sneaking on the radar on a red day.
No comment yet